ABT 413
Alternative Names: ABT-413Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Antirheumatics
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA
- 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie